← Back to Search

Geriatric Assessment for Cancer Survivorship

N/A
Recruiting
Led By Haifaa Abdulhaq, MD
Research Sponsored by University of California, San Francisco
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age 65 years and above
Diagnosis of cancer and completion of chemotherapy with curative intent
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4-6 months
Awards & highlights

Study Summary

This trial will test whether giving an older cancer survivor a care plan and follow-up visit improves their quality of life.

Who is the study for?
This trial is for adults aged 65 or older who have finished chemotherapy with the goal of curing cancer. They must be scheduled to receive a survivorship care plan from an oncology navigator and able to participate in interviews. It's not for those with advanced dementia, serious cognitive issues, or nursing home residents.Check my eligibility
What is being tested?
The study is testing if adding a geriatric assessment visit after giving older adults a survivorship care plan can improve their quality of life and satisfaction with care post-chemotherapy compared to just receiving the care plan alone.See study design
What are the potential side effects?
Since this trial involves assessments rather than medications, there are no direct side effects like you'd expect from drugs. However, participants may experience emotional or psychological impacts when discussing their health and experiences.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 65 years old or older.
Select...
I have cancer and finished chemotherapy aimed at curing it.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4-6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4-6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Acceptability of the study: survey
Number of months needed for completion of trial enrollment
Study retention rate
Secondary outcome measures
Health related quality of life assessment by QLQ14
Health related quality of life assessment by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire EORTC QLQ-30
Patient satisfaction assessment by PSCC (Patient Satisfaction with Cancer related Care) tool
+1 more

Trial Design

2Treatment groups
Active Control
Group I: No intervention armActive Control1 Intervention
routine care only; will not be scheduled for comprehensive geriatric assessment
Group II: Active comparator armActive Control1 Intervention
those that will be scheduled for comprehensive geriatric assessment with a geriatric nurse practitioner or physician

Find a Location

Who is running the clinical trial?

University of California, San FranciscoLead Sponsor
2,496 Previous Clinical Trials
11,933,419 Total Patients Enrolled
Haifaa Abdulhaq, MDPrincipal InvestigatorUniversity of California, San Francisco

Media Library

Active comparator arm Clinical Trial Eligibility Overview. Trial Name: NCT04405115 — N/A
Survivorship Research Study Groups: No intervention arm, Active comparator arm
Survivorship Clinical Trial 2023: Active comparator arm Highlights & Side Effects. Trial Name: NCT04405115 — N/A
Active comparator arm 2023 Treatment Timeline for Medical Study. Trial Name: NCT04405115 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the total number of participants enrolled in this investigation?

"Affirmative. According to clinicaltrials.gov, this scientific trial is actively recruiting participants; it was initially posted on February 16th 2021 and underwent its most recent update on March 22nd 2022. The research requires 70 individuals from 1 medical facility."

Answered by AI

What are the chief aims of this trial?

"This medical study is expected to take between 4-6 months, with the primary outcome being completion rates. Secondary objectives include evaluating patient health and quality of life through QLQ-ELD14 that assesses mobility, worries about others, future worries, maintaining purpose and burden of illness alongside two single items (joint stiffness and family support). Additionally, self rated knowledge will be evaluated using PLANS assessment tool which measures survivor satisfaction along a four point scale. Lastly, Patient Satisfaction with Cancer related Care tool (PSCC) will measure participant's level of agreement on five point Likert scales in order to gauge their overall satisfaction."

Answered by AI

Are investigators still enrolling participants in this research?

"Reports from clinicaltrials.gov confirm that this medical trial is currently recruiting patients, with the initial listing posted on February 16th 2021 and last updated on March 22nd 2022."

Answered by AI
~19 spots leftby May 2025